Abstract

Defective clearance mechanisms lead to the accumulation of amyloid-beta (Aβ) peptides in the Alzheimer’s brain. Though predominantly generated in neurons, little is known about how these hydrophobic, aggregation-prone, and tightly membrane-associated peptides exit into the extracellular space where they deposit and propagate neurotoxicity. The ability for P-glycoprotein (P-gp), an ATP-binding cassette (ABC) transporter, to export Aβ across the blood-brain barrier (BBB) has previously been reported. However, controversies surrounding the P-gp–Aβ interaction persist. Here, molecular data affirm that both Aβ40 and Aβ42 peptide isoforms directly interact with and are substrates of P-gp. This was reinforced ex vivo by the inhibition of Aβ42 transport in brain capillaries from P-gp-knockout mice. Moreover, we explored whether P-gp could exert the same role in neurons. Comparison between non-neuronal CHO-APP and human neuroblastoma SK-N-SH cells revealed that P-gp is expressed and active in both cell types. Inhibiting P-gp activity using verapamil and nicardipine impaired Aβ40 and Aβ42 secretion from both cell types, as determined by ELISA. Collectively, these findings implicate P-gp in Aβ export from neurons, as well as across the BBB endothelium, and suggest that restoring or enhancing P-gp function could be a viable therapeutic approach for removing excess Aβ out of the brain in Alzheimer’s disease.

Highlights

  • The accumulation of amyloid-beta (Aβ) peptides in the brain is a key pathological hallmark of Alzheimer’s disease (AD)

  • Verapamil yielded as physiological ratios observed in human AD brains [52,66]

  • Aβ peptide suggests that simple diffusion, as it has until now been assumed, does not adequately explain the mechanism of its expulsion into the extracellular space

Read more

Summary

Introduction

The accumulation of amyloid-beta (Aβ) peptides in the brain is a key pathological hallmark of Alzheimer’s disease (AD). Aβ40 and the more hydrophobic and aggregation-prone Aβ42 are the most common isoforms, with a higher ratio of Aβ42 : Aβ40 being associated with increased neurotoxicity, and accelerated disease pathology and cognitive decline [2]. In the brain, these peptides are constitutively produced in neurons and astrocytes following enzymatic cleavage of the transmembrane amyloid precursor protein (APP), and subsequently rapidly cleared [3,4,5]. Excess levels of soluble oligomeric Aβ have been demonstrated to impair long-term potentiation, drive synaptic and receptor dysfunction, propagate tau pathology, neuroinflammation, and oxidative stress, and correlate with disease severity [7,8,9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call